Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
4.050
+0.090 (2.27%)
At close: Dec 20, 2024, 4:00 PM
4.060
+0.010 (0.25%)
After-hours: Dec 20, 2024, 4:26 PM EST
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for AMLX stock have an average target of 7.60, with a low estimate of 3.00 and a high estimate of 12. The average target predicts an increase of 87.65% from the current stock price of 4.05.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AMLX stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 5 | 5 | 5 | 5 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +196.30% | Dec 5, 2024 |
| Baird | Baird | Hold → Buy Upgrades $3 → $11 | Hold → Buy | Upgrades | $3 → $11 | +171.60% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $12 | Strong Buy | Maintains | $8 → $12 | +196.30% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +97.53% | Oct 18, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $3 → $4 | Hold | Maintains | $3 → $4 | -1.23% | Jul 12, 2024 |
Financial Forecast
Revenue This Year
89.69M
from 380.79M
Decreased by -76.45%
Revenue Next Year
n/a
from 89.69M
EPS This Year
-4.42
from 0.70
EPS Next Year
-1.79
from -4.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 92.4M | n/a | 677,250 | |||
| Avg | 89.7M | n/a | 328,950 | |||
| Low | 85.8M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -75.7% | - | - | |||
| Avg | -76.4% | - | - | |||
| Low | -77.5% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -4.33 | -1.06 | -1.05 |
| Avg | -4.42 | -1.79 | -1.68 |
| Low | -4.38 | -2.49 | -2.38 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.